This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: Patient registries are valuable because they provide data that cannot be captured in any other way. Observations from registry studies are particularly informative if multiple registries confirm similar findings. A selection of multiple sclerosis (MS) registry studies were reviewed, and results and consistency of those studies are presented.
Methods: A panel of experts analyzed the study findings of established MS registries and presented their conclusions on the overall results and consistency of those studies.
Results: A review of evidence from MS registry studies reveals similar findings with respect to patterns of disability progression, predictors of disability progression, and changes in lifespan. Several registries show that progression after Expanded Disability Status Scale (EDSS) 4 occurs at a predictable rate, and once EDSS 4 is reached, subsequent progression rates are similar regardless of the type of MS at onset. Clinicians, payers, and patients need to understand that MS may shorten life expectancy. The mortality data derived from registries reveal higher death rates in patients with MS compared with the general population, indicating that MS is an important public health issue.
Conclusions: The key findings in registries should be utilized in conjunction with data from clinical trials to optimize treatment and improve long-term outcomes.
Footnotes
-
- BCMS
- British Columbia Multiple Sclerosis
- CDMS
- clinically definite multiple sclerosis
- DMT
- disease-modifying therapy
- EDMUS
- European Database for Multiple Sclerosis
- EDSS
- Expanded Disability Status Scale
- IFN
- interferon
- MS
- multiple sclerosis
- NYSMSC
- New York State Multiple Sclerosis Consortium
- PPMS
- primary progressive multiple sclerosis
- PRMS
- primary relapsing multiple sclerosis
- RRMS
- relapsing-remitting multiple sclerosis
- SPMS
- secondary progressive multiple sclerosis.
-
This Neurology® supplement is not peer-reviewed. Information contained in this Neurology® supplement represents the opinions of the authors. These opinions are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology®.
- Copyright © 2010 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.